Please enable JavaScript to continue using this application.

Compare $AKTS vs $RIGL | Chartloom

Compare

$AKTS vs $RIGL

Aktis Oncology Inc · Rigel Pharmaceuticals Inc

AKTS

Aktis Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Compare $AKTS vs $RIGL

Comparing Aktis Oncology Inc and Rigel Pharmaceuticals Inc

AKTSAktis Oncology Inc

RIGLRigel Pharmaceuticals Inc

AKTSAktis Oncology Inc

Market cap

$969M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

99.47x

Rev growth (TTM)

49.9%

YTD performance

-19.0%

52W performance

18688.8%

FCF yield

-12.6%

RIGLRigel Pharmaceuticals Inc

Market cap

$908M

P/E (TTM)

2.98x

Forward P/E (NTM)

15.85x

Forward P/S (NTM)

2.61x

Rev growth (TTM)

3.3%

YTD performance

17.3%

52W performance

70.7%

FCF yield

1.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKTS

RIGL

Detailed metrics comparison

AKTS

Aktis Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

AKTS$969M

RIGL$908M

Enterprise Value

AKTS$887M

RIGL$886M

Price

AKTS$18.15

RIGL$49.08

P/E Ratio

AKTSN/A

RIGL2.98x

P/S Ratio

AKTS73.94x

RIGL3.28x

EV/Sales

AKTS67.65x

RIGL3.20x

EV/EBITDA

AKTS0.00x

RIGL9.50x

P/B Ratio

AKTS2.12x

RIGL2.07x

P/FCF Ratio

AKTSN/A

RIGL100.69x

EV/FCF

AKTS-7.29x

RIGL98.29x

PEG Ratio

AKTSN/A

RIGL0.01x

Forward P/E (NTM)

AKTSN/A

RIGL15.85x

Forward P/S (NTM)

AKTS99.47x

RIGL2.61x

Revenue (TTM)

AKTS$13M

RIGL$277M

Revenue Growth (YoY)

AKTS49.9%

RIGL3.3%

Forward Rev Growth

AKTS-9.8%

RIGL21.9%

Gross Margin (TTM)

AKTS0.0%

RIGL91.4%

Operating Margin (TTM)

AKTS0.0%

RIGL31.4%

EBITDA Margin (TTM)

AKTS-934.0%

RIGL32.4%

Net Margin (TTM)

AKTS-810.2%

RIGL116.3%

FCF Margin (TTM)

AKTS-928.1%

RIGL3.3%

Net Income (TTM)

AKTS$-106M

RIGL$322M

FCF (TTM)

AKTS$-122M

RIGL$9M

EPS (TTM)

AKTS-$1.92

RIGL$16.45

ROE (TTM)

AKTS-3080.0%

RIGL96.5%

ROA (TTM)

AKTS-2531.0%

RIGL72.3%

ROIC (TTM)

AKTS-3080.0%

RIGL84.1%

Cash

AKTS$82M

RIGL$61M

Debt

AKTS$0

RIGL$39M

Net Cash/Debt

AKTS$82M

RIGL$22M

Current Ratio (TTM)

AKTS16.33x

RIGL1.94x

Quick Ratio (TTM)

AKTS16.10x

RIGL1.58x

Debt/Equity (TTM)

AKTS0.00x

RIGL0.09x

Debt/Assets (TTM)

AKTS0.0%

RIGL0.0%

Interest Coverage (TTM)

AKTSN/A

RIGLN/A

Net Debt/EBITDA (TTM)

AKTS0.00x

RIGL0.00x

Beta

AKTS160.56

RIGL1.26

52W Performance

AKTS18688.8%

RIGL70.7%

YTD Performance

AKTS-19.0%

RIGL17.3%

% from 52W High

AKTS-46.9%

RIGL-6.0%

% from 52W Low

AKTS907400.0%

RIGL96.7%

Asset Turnover (TTM)

AKTS0.03x

RIGL0.62x

FCF Yield (TTM)

AKTS-12.6%

RIGL1.0%

Earnings Yield (TTM)

AKTS-11.0%

RIGL35.5%

Dividend Yield (TTM)

AKTSN/A

RIGLN/A

Rule of 40

AKTS-878.2

RIGL6.6

EV/GP/RG

AKTSN/A

RIGL0.13

Ticker research

View AKTS research View RIGL research

Metric	AKTS Aktis Oncology Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$969M	$908M
Enterprise Value	$887M	$886M
Price	$18.15	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	73.94x	3.28x
EV/Sales	67.65x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	2.12x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-7.29x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	99.47x	2.61x
Revenue & Growth
Revenue (TTM)	$13M	$277M
Revenue Growth (YoY)	49.9%	3.3%
Forward Rev Growth	-9.8%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-934.0%	32.4%
Net Margin (TTM)	-810.2%	116.3%
FCF Margin (TTM)	-928.1%	3.3%
Net Income (TTM)	$-106M	$322M
FCF (TTM)	$-122M	$9M
EPS (TTM)	-$1.92	$16.45
ROE (TTM)	-3080.0%	96.5%
ROA (TTM)	-2531.0%	72.3%
ROIC (TTM)	-3080.0%	84.1%
Financial Health
Cash	$82M	$61M
Debt	$0	$39M
Net Cash/Debt	$82M	$22M
Current Ratio (TTM)	16.33x	1.94x
Quick Ratio (TTM)	16.10x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	160.56	1.26
52W Performance	18688.8%	70.7%
YTD Performance	-19.0%	17.3%
% from 52W High	-46.9%	-6.0%
% from 52W Low	907400.0%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.03x	0.62x
FCF Yield (TTM)	-12.6%	1.0%
Earnings Yield (TTM)	-11.0%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-878.2	6.6
EV/GP/RG	N/A	0.13
Ticker research	View AKTS research	View RIGL research

Valuation

P/E Ratio

RIGL

2.98x

P/S Ratio

RIGL

3.28x

AKTS

73.94x

EV/FCF

AKTS

-7.29x

RIGL

98.29x

Growth & revenue

Revenue Growth TTM

AKTS

49.9%

RIGL

3.3%

Forward Revenue Growth

RIGL

21.9%

AKTS

-9.8%

Profitability & performance

Gross Margin

RIGL

91.4%

AKTS

0.0%

ROE

RIGL

96.5%

AKTS

-3080.0%

FCF Yield %

RIGL

1.0%

AKTS

-12.6%

52-Week Performance

AKTS

18688.8%

RIGL

70.7%

Detailed metrics comparison

AKTS

Aktis Oncology Inc

RIGL

Rigel Pharmaceuticals Inc

Market Cap

AKTS$969M

RIGL$908M

Enterprise Value

AKTS$887M

RIGL$886M

Price

AKTS$18.15

RIGL$49.08

P/E Ratio

AKTSN/A

RIGL2.98x

P/S Ratio

AKTS73.94x

RIGL3.28x

EV/Sales

AKTS67.65x

RIGL3.20x

EV/EBITDA

AKTS0.00x

RIGL9.50x

P/B Ratio

AKTS2.12x

RIGL2.07x

P/FCF Ratio

AKTSN/A

RIGL100.69x

EV/FCF

AKTS-7.29x

RIGL98.29x

PEG Ratio

AKTSN/A

RIGL0.01x

Forward P/E (NTM)

AKTSN/A

RIGL15.85x

Forward P/S (NTM)

AKTS99.47x

RIGL2.61x

Revenue (TTM)

AKTS$13M

RIGL$277M

Revenue Growth (YoY)

AKTS49.9%

RIGL3.3%

Forward Rev Growth

AKTS-9.8%

RIGL21.9%

Gross Margin (TTM)

AKTS0.0%

RIGL91.4%

Operating Margin (TTM)

AKTS0.0%

RIGL31.4%

EBITDA Margin (TTM)

AKTS-934.0%

RIGL32.4%

Net Margin (TTM)

AKTS-810.2%

RIGL116.3%

FCF Margin (TTM)

AKTS-928.1%

RIGL3.3%

Net Income (TTM)

AKTS$-106M

RIGL$322M

FCF (TTM)

AKTS$-122M

RIGL$9M

EPS (TTM)

AKTS-$1.92

RIGL$16.45

ROE (TTM)

AKTS-3080.0%

RIGL96.5%

ROA (TTM)

AKTS-2531.0%

RIGL72.3%

ROIC (TTM)

AKTS-3080.0%

RIGL84.1%

Cash

AKTS$82M

RIGL$61M

Debt

AKTS$0

RIGL$39M

Net Cash/Debt

AKTS$82M

RIGL$22M

Current Ratio (TTM)

AKTS16.33x

RIGL1.94x

Quick Ratio (TTM)

AKTS16.10x

RIGL1.58x

Debt/Equity (TTM)

AKTS0.00x

RIGL0.09x

Debt/Assets (TTM)

AKTS0.0%

RIGL0.0%

Interest Coverage (TTM)

AKTSN/A

RIGLN/A

Net Debt/EBITDA (TTM)

AKTS0.00x

RIGL0.00x

Beta

AKTS160.56

RIGL1.26

52W Performance

AKTS18688.8%

RIGL70.7%

YTD Performance

AKTS-19.0%

RIGL17.3%

% from 52W High

AKTS-46.9%

RIGL-6.0%

% from 52W Low

AKTS907400.0%

RIGL96.7%

Asset Turnover (TTM)

AKTS0.03x

RIGL0.62x

FCF Yield (TTM)

AKTS-12.6%

RIGL1.0%

Earnings Yield (TTM)

AKTS-11.0%

RIGL35.5%

Dividend Yield (TTM)

AKTSN/A

RIGLN/A

Rule of 40

AKTS-878.2

RIGL6.6

EV/GP/RG

AKTSN/A

RIGL0.13

Ticker research

View AKTS research View RIGL research

Metric	AKTS Aktis Oncology Inc	RIGL Rigel Pharmaceuticals Inc
Market & Valuation
Market Cap	$969M	$908M
Enterprise Value	$887M	$886M
Price	$18.15	$49.08
P/E Ratio	N/A	2.98x
P/S Ratio	73.94x	3.28x
EV/Sales	67.65x	3.20x
EV/EBITDA	0.00x	9.50x
P/B Ratio	2.12x	2.07x
P/FCF Ratio	N/A	100.69x
EV/FCF	-7.29x	98.29x
PEG Ratio	N/A	0.01x
Forward P/E (NTM)	N/A	15.85x
Forward P/S (NTM)	99.47x	2.61x
Revenue & Growth
Revenue (TTM)	$13M	$277M
Revenue Growth (YoY)	49.9%	3.3%
Forward Rev Growth	-9.8%	21.9%
Profitability
Gross Margin (TTM)	0.0%	91.4%
Operating Margin (TTM)	0.0%	31.4%
EBITDA Margin (TTM)	-934.0%	32.4%
Net Margin (TTM)	-810.2%	116.3%
FCF Margin (TTM)	-928.1%	3.3%
Net Income (TTM)	$-106M	$322M
FCF (TTM)	$-122M	$9M
EPS (TTM)	-$1.92	$16.45
ROE (TTM)	-3080.0%	96.5%
ROA (TTM)	-2531.0%	72.3%
ROIC (TTM)	-3080.0%	84.1%
Financial Health
Cash	$82M	$61M
Debt	$0	$39M
Net Cash/Debt	$82M	$22M
Current Ratio (TTM)	16.33x	1.94x
Quick Ratio (TTM)	16.10x	1.58x
Debt/Equity (TTM)	0.00x	0.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	160.56	1.26
52W Performance	18688.8%	70.7%
YTD Performance	-19.0%	17.3%
% from 52W High	-46.9%	-6.0%
% from 52W Low	907400.0%	96.7%
Efficiency & Yields
Asset Turnover (TTM)	0.03x	0.62x
FCF Yield (TTM)	-12.6%	1.0%
Earnings Yield (TTM)	-11.0%	35.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-878.2	6.6
EV/GP/RG	N/A	0.13
Ticker research	View AKTS research	View RIGL research